Jubilant Pharmova liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

2.54×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.62×	1.62×	1.62×	1.92×	2.12×
1.13×	1.13×	1.10×	1.24×	1.34×
1,267	1,267	1,088	956	1,014
1,570	1,570	1,345	1,743	1,990

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JUBLPHARMA₹946.00

Jubilant Pharmova Ltd.

· Pharma & Health

₹ CrorePeersGLAND PPLPHARMA KIMS INDGN ONESOURCE GRANULES PFIZER POLYMEDMcap ₹14,947 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	2.54
Current Ratio	2.12	1.92	1.62	1.62	1.62
Quick Ratio	1.34	1.24	1.10	1.13	1.13
Cash, Equiv & ST Investments	1,013.9	956.4	1,088.3	1,267.1	1,267.1
Working Capital	1,990.0	1,743.2	1,345.1	1,570.4	1,570.4

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.